Exelixis (EXEL) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is EXEL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript…

Cabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.…

Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the finish line.…

Exelixis NASDAQ: EXEL is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief Strategy Officer Andrew Pete…

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript…

Exelixis NASDAQ: EXEL is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters said at a conference d…

Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript…

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.…

Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.…

Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript…

Exelixis NASDAQ: EXEL reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of zanzalintinib in colorectal c…

Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and t…

Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.78 per share a year ago.…

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its c…

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exe…

Regulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug. However, the company's most important medicine is performing well and still has several years of growth before facing …

Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.…

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to s…

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healt…

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), t…

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to sh…

Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 12. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

